ABSTRACT
Objectives: More than 40 drugs are available to treat affective disorders. Individual selection of the optimal drug and dose is required to attain the highest possible efficacy and acceptable tolerability for every patient.Methods: This review, which includes more than 500 articles selected by 30 experts, combines relevant knowledge on studies investigating the pharmacokinetics, pharmacodynamics and pharmacogenetics of 33 antidepressant drugs and of 4 drugs approved for augmentation in cases of insufficient response to antidepressant monotherapy. Such studies typically measure drug concentrations in blood (i.e. therapeutic drug monitoring) and genotype relevant genetic polymorphisms of enzymes, transporters or receptors involved in drug metabolism or mechanism of action. Imaging studies, primarily positron emission tomography that relates drug concentrations in blood and radioligand binding, are considered to quantify target structure occupancy by the antidepressant drugs in vivo. Results: Evidence is given that in vivo imaging, therapeutic drug monitoring and genotyping and/or phenotyping of drug metabolising enzymes should be an integral part in the development of any new antidepressant drug.Conclusions: To guide antidepressant drug therapy in everyday practice, there are multiple indications such as uncertain adherence, polypharmacy, nonresponse and/or adverse reactions under therapeutically recommended doses, where therapeutic drug monitoring and cytochrome P450 genotyping and/or phenotyping should be applied as valid tools of precision medicine.
Subject(s)
Pharmacogenetics , Psychiatry , Antidepressive Agents/pharmacology , Drug Monitoring , Humans , NeuroimagingABSTRACT
PURPOSE: Optical coherence tomography angiography (OCTA) allows for the non-invasive, three-dimensional visualization of retinal and chorioidal vascular structures. In this study, this new imaging modality was evaluated in rats. METHODS: In vivo imaging in Dark Agouti rats was performed using confocal scanning laser ophthalmoscopy (cSLO) and OCTA (Spectralis prototype, Heidelberg Engineering) after adjusting the length of the reference arm. The OCTA en-face images were compared to conventional fluorescein angiography cSLO images. The histological examination allowed for correlation of retinal and chorioidal plexus. RESULTS: While the diagnostic device was developed for use in humans, OCTA and cSLO imaging can be applied in rodents after only minor hardware modifications. High-resolution and contrast-enhanced images enable a depth-selective visualization of the three retinal plexus and the inner and outer chorioidal vascular networks. In comparison to fluorescein angiography (FA), OCTA is characterized by higher resolution and more accurate three-dimensional localization of vascular structures, particularly in deep layers. A current limitation includes the relatively small area imaged by OCTA. DISCUSSION: The recently developed OCTA imaging technology also allows for three-dimensional detection of retinal and chorioidal vascular changes in vivo without dye injection in rodents. OCT may potentially replace invasive FA for specific questions and will be useful in animal models for research of retinal and chorioidal angiogenic processes physiologically and during pharmacological interventions.
Subject(s)
Diagnostic Techniques, Ophthalmological/instrumentation , Diagnostic Techniques, Ophthalmological/veterinary , Microscopy, Confocal/instrumentation , Microscopy, Confocal/veterinary , Retinal Vessels/anatomy & histology , Tomography, Optical Coherence/instrumentation , Tomography, Optical Coherence/veterinary , Animals , Equipment Design , Equipment Failure Analysis , Rats , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
OBJECTIVE: To investigate the effects of light therapy on serotonin transporter binding (5-HTT BPND ), an index of 5-HTT levels, in the anterior cingulate and prefrontal cortices (ACC and PFC) during winter in seasonal affective disorder (SAD). 5-HTT BPND fluctuates seasonally to a greater extent in SAD relative to health. We hypothesized that in SAD, 5-HTT BPND would be reduced in the ACC and PFC following light therapy. METHODS: Eleven SAD participants underwent [11 C] DASB positron emission tomography (PET) scans to measure 5-HTT BPND before and after 2 weeks of daily morning light therapy. RESULTS: The primary finding was a main effect of treatment on 5-HTT BPND in the ACC and PFC (repeated-measures manova, F(2,9) = 6.82, P = 0.016). This effect was significant in the ACC (F(1,10) = 15.11 and P = 0.003, magnitude of decrease, 11.94%) and PFC (F(1,10) = 8.33, P = 0.016, magnitude of decrease, 9.13%). 5-HTT BPND also decreased in other regions assayed following light therapy (repeated-measures manova, F(4,7) = 8.54, P = 0.028) including the hippocampus, ventral striatum, dorsal putamen, thalamus and midbrain (F(1,10) = 8.02-36.94, P < 0.0001-0.018; magnitude -8.83% to -16.74%). CONCLUSIONS: These results demonstrate that light therapy reaches an important therapeutic target in the treatment of SAD and provide a basis for improvement of this treatment via application of [11 C]DASB PET.
Subject(s)
Phototherapy/methods , Seasonal Affective Disorder/therapy , Serotonin Plasma Membrane Transport Proteins/metabolism , Adult , Female , Gyrus Cinguli/metabolism , Humans , Male , Positron-Emission Tomography/methods , Prefrontal Cortex/metabolism , Protein Binding , Seasonal Affective Disorder/metabolism , Treatment OutcomeABSTRACT
OBJECTIVE: To investigate the effects of light therapy on serotonin transporter binding (5-HTT BPND ), an index of 5-HTT levels, in the anterior cingulate and prefrontal cortices (ACC and PFC) of healthy individuals during the fall and winter. Twenty-five per cent of healthy individuals experience seasonal mood changes that affect functioning. 5-HTT BPND has been found to be higher across multiple brain regions in the fall and winter relative to spring and summer, and elevated 5-HTT BPND may lead to extracellular serotonin loss and low mood. We hypothesized that, during the fall and winter, light therapy would reduce 5-HTT BPND in the ACC and PFC, which sample brain regions involved in mood regulation. METHOD: In a single-blind, placebo-controlled, counterbalanced, crossover design, [(11) C]DASB positron emission tomography was used measure 5-HTT BPND following light therapy and placebo conditions during fall and winter. RESULTS: In winter, light therapy significantly decreased 5-HTT BPND by 12% in the ACC relative to placebo (F1,9 = 18.04, P = 0.002). In the fall, no significant change in 5-HTT BPND was found in any region across conditions. CONCLUSION: These results identify, for the first time, a central biomarker associated with the intervention of light therapy in humans which may be applied to further develop this treatment for prevention of seasonal depression.
Subject(s)
Gyrus Cinguli/metabolism , Phototherapy/methods , Positron-Emission Tomography/methods , Prefrontal Cortex/metabolism , Seasons , Serotonin Plasma Membrane Transport Proteins/metabolism , Adult , Biomarkers/metabolism , Cross-Over Studies , Female , Humans , Male , Phototherapy/instrumentation , Protein Binding , Single-Blind Method , Young AdultABSTRACT
One of the cellular markers of neuroinflammation is increased microglia activation, characterized by overexpression of mitochondrial 18kDa Translocator Protein (TSPO). TSPO expression can be quantified in-vivo using the positron emission tomography (PET) radioligand [(18)F]-FEPPA. This study examined microglial activation as measured with [(18)F]-FEPPA PET across the adult lifespan in a group of healthy volunteers. We performed genotyping for the rs6971 TS.PO gene polymorphism to control for the known variability in binding affinity. Thirty-three healthy volunteers (age range: 19-82years; 22 high affinity binders (HAB), 11 mixed affinity binders (MAB)) underwent [(18)F]-FEPPA PET scans, acquired on the High Resolution Research Tomograph (HRRT) and analyzed using a 2-tissue compartment model. Regression analyses were performed to examine the effect of age adjusting for genetic status on [(18)F]-FEPPA total distribution volumes (VT) in the hippocampus, temporal, and prefrontal cortex. We found no significant effect of age on [(18)F]-FEPPA VT (F (1,30)=0.918; p=0.346), and a significant effect of genetic polymorphism (F (1,30)=8.767; p=0.006). This is the first in-vivo study to evaluate age-related changes in TSPO binding, using the new generation TSPO radioligands. Increased neuroinflammation, as measured with [(18)F]-FEPPA PET was not associated with normal aging, suggesting that healthy elderly individuals may serve as useful benchmark against patients with neurodegenerative disorders where neuroinflammation may be present.
Subject(s)
Aging/metabolism , Anilides , Brain/diagnostic imaging , Pyridines , Radiopharmaceuticals , Receptors, GABA/metabolism , Aging/pathology , Brain/metabolism , Female , Fluorine Radioisotopes , Humans , Image Interpretation, Computer-Assisted , Inflammation/diagnostic imaging , Inflammation/metabolism , Male , Microglia/diagnostic imaging , Microglia/metabolism , Middle Aged , Positron-Emission Tomography , Receptors, GABA/analysisABSTRACT
AIMS/HYPOTHESES: Glucagon-like peptide-1 (GLP-1), an important mediator of postprandial glycaemia, could potentially be stimulated by delivering small quantities of nutrient to a long length of distal gut. We aimed to determine whether enteric-coated pellets, releasing small amounts of lauric acid throughout the ileum and colon, could reduce glycaemic responses to meals in type 2 diabetes, associated with stimulation of GLP-1. METHODS: Eligible patients, who had type 2 diabetes controlled by diet or metformin, were each studied on two occasions in a hospital setting. After an overnight fast, patients consumed 5 g active pellets (47% lauric acid by weight) or placebo with breakfast (T = 0 min) and lunch (T = 240 min), in a crossover design with order randomised by the hospital pharmacy and allocation concealed by numbered containers. Patients and investigators making measurements were blinded to the intervention. Blood was sampled frequently for blood glucose (the primary outcome) and hormone assays. RESULTS: Eight patients were randomised (four to receive either intervention first), and all completed the study without adverse effects. Blood glucose was lower after breakfast (T = 0-240 min, area under the curve (AUC) 2,075 ± 368 vs 2,216 ± 163 mmol/l × min) and lunch (T = 240-480 min, AUC 1,916 ± 115 vs 2,088 ± 151 mmol/l × min) (p = 0.02 for each) after active pellets than after placebo. Plasma GLP-1 concentrations were higher after breakfast (p = 0.08) and lunch (p = 0.04) for active pellets. While there were no differences in insulin or glucose-dependent insulinotropic polypeptide concentrations, glucagon concentrations were higher after breakfast and lunch (p = 0.002 for each) for active pellets. CONCLUSIONS/INTERPRETATION: Delivering small amounts of nutrient to the ileum and colon can stimulate substantial endogenous GLP-1 release and attenuate postprandial glycaemia. This novel approach has therapeutic potential in type 2 diabetes. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12612000600842. FUNDING: The study was funded by Meyer Nutriceuticals.
Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Glucagon-Like Peptide 1/metabolism , Hyperglycemia/complications , Tablets, Enteric-Coated/therapeutic use , Area Under Curve , Blood Glucose/metabolism , Colon/metabolism , Cross-Over Studies , Female , Glucagon/metabolism , Humans , Ileum/metabolism , Insulin/metabolism , Lauric Acids/therapeutic use , Male , Metformin/therapeutic use , Middle Aged , Time FactorsABSTRACT
The plasma dynamics of single mesoscopic Xe particles irradiated with intense femtosecond x-ray pulses exceeding 10(16) W/cm2 from the Linac Coherent Light Source free-electron laser are investigated. Simultaneous recording of diffraction patterns and ion spectra allows eliminating the influence of the laser focal volume intensity and particle size distribution. The data show that for clusters illuminated with intense x-ray pulses, highly charged ionization fragments in a narrow distribution are created and that the nanoplasma recombination is efficiently suppressed.
ABSTRACT
It is estimated that 15% of all individuals will experience a major depressive episode (MDE) during their lifetime and that treatment response is inadequate in 40% of these cases. To address this, neuroimaging is being used to identify MDE subtypes and mechanisms of onset as well as to optimize target occupancy of novel treatments. Neuroimaging of monoamine oxidase-A (MAO-A) binding; glutamate levels; indexes of 5-HT(2A), 5-HTT, 5-HT(1A), and 5-HT(1B) receptors; levels of dopamine transporters D(1) and D(2); and hippocampal volume are described here. Three themes emerge. First, symptoms such as pessimism, motor retardation, anxiety disorder, and verbal memory deficits best indicate the subtype of depression. Second, measures related to mechanisms of monoamine loss, particularly elevated MAO-A binding in prefrontal and anterior cingulate cortex, are present in MDE and in high-risk states for MDE. Third, clinical trials show a consistent 80% 5-HTT occupancy of selective serotonin reuptake inhibitors at doses sufficient to distinguish from placebo in clinical trials (although in vitro affinities vary 100-fold), thereby supporting the need for further occupancy studies to accelerate therapeutic development.
Subject(s)
Depressive Disorder, Major/diagnosis , Depressive Disorder, Major/metabolism , Neuroimaging/psychology , Selective Serotonin Reuptake Inhibitors/pharmacology , Brain/diagnostic imaging , Brain/drug effects , Brain/metabolism , Depressive Disorder, Major/diagnostic imaging , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/prevention & control , Drug Discovery/methods , Glutamic Acid/metabolism , Humans , Models, Neurological , Monoamine Oxidase/metabolism , Neuroimaging/methods , Neuroimaging/statistics & numerical data , Precision Medicine/methods , Radionuclide Imaging , Receptors, Dopamine/metabolism , Receptors, Serotonin/metabolism , Serotonin Plasma Membrane Transport Proteins/metabolism , Selective Serotonin Reuptake Inhibitors/therapeutic useABSTRACT
BACKGROUND: Monoamine oxidase A (MAOA) is an important enzyme that metabolizes monoamines such as serotonin, norepinephrine and dopamine in the brain. In prefrontal cortex, low MAOA binding is associated with aggression and high binding is associated with major depressive disorder (MDD) and also risk for recurrence of depressive episodes. In rodent models, low MAOA levels are associated with increased aggression and fear conditioning, and decreased social and exploratory investigative behaviors. Our objective was to measure MAOA binding in prefrontal cortex and concurrently evaluate a broad range of validated personality traits. We hypothesized that prefrontal MAOA binding would correlate negatively with angry-hostility, a trait related to aggression/anger, and positively with traits intuitively related to adaptive investigative behavior. METHOD: Participants were aged 19-49 years, healthy and non-smoking. MAOA binding was measured with [11C]harmine positron emission tomography (PET) in prefrontal brain regions and personality traits were measured with the NEO Personality Inventory Revised (NEO PI-R). RESULTS: Prefrontal MAOA binding correlated negatively with angry-hostility (r=-0.515, p=0.001) and positively with deliberation (r=0.514, p=0.001). In a two-factor regression model, these facets explained 38% of variance in prefrontal MAOA binding. A similar relationship was found in prefrontal cortex subregions. CONCLUSIONS: We propose a new continuum describing the relationship between personality and MAOA: deliberate/thoughtful contrasting aggressive/impulsive. Additionally, the association between high MAOA binding and greater deliberation may explain why some people have moderately high levels of MAOA, although very high levels occur during MDD. In health, higher MAOA binding is associated with an adaptive personality facet.
Subject(s)
Anger/physiology , Hostility , Monoamine Oxidase/metabolism , Personality , Prefrontal Cortex/enzymology , Adaptation, Psychological , Adult , Aggression/physiology , Female , Humans , Impulsive Behavior , Male , Middle Aged , Personality Inventory , Positron-Emission TomographyABSTRACT
This study examined the effects of the lipase inhibitor, orlistat, on gastric emptying of, and the glycemic and incretin hormone responses to, a drink containing oil and glucose components in patients with type 2 diabetes. Seven patients (aged 58 +/- 5 yr), managed by diet alone, consumed 60 ml olive oil (labeled with 20 MBq (99m)Tc-V-thiocyanate) and 300 ml water containing 75 g glucose (labeled with 6 MBq (67)Ga-EDTA), on two occasions, with and without 120 mg orlistat, positioned in the left lateral decubitus position with their back against a gamma camera. Venous blood samples, for measurement of blood glucose and plasma insulin, glucagon-like peptide-1 and glucose-dependent insulintropic polypeptide were obtained immediately before, and after, the drink. Gastric emptying of both oil (P < 0.001) and glucose (P < 0.0005) was faster after orlistat compared with control. Postprandial blood glucose (P < 0.001) and plasma insulin (P < 0.05) were substantially greater after orlistat compared with control. In contrast, plasma glucagon-like peptide-1 (P < 0.005) and glucose-dependent insulintropic polypeptide (P < 0.05) were less after orlistat. In conclusion, inhibition of fat digestion, by orlistat, may exacerbate postprandial glycemia, as a result of more rapid gastric emptying and a diminished incretin response.
Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Type 2/blood , Dietary Fats/pharmacology , Enzyme Inhibitors/pharmacology , Gastric Emptying/physiology , Glucose/pharmacology , Lactones/pharmacology , Lipase/antagonists & inhibitors , Peptide Fragments/blood , Autonomic Nervous System/drug effects , Autonomic Nervous System/physiology , Female , Gastric Inhibitory Polypeptide/blood , Gastric Mucosa/metabolism , Glucagon , Glucagon-Like Peptide 1 , Glucagon-Like Peptides , Hemodynamics/drug effects , Hemodynamics/physiology , Humans , Insulin/blood , Male , Middle Aged , Orlistat , Peptides/bloodABSTRACT
Previous studies suggest that there is a dopamine lowering process during major depressive episodes (MDE). To investigate this, we measured the dopamine transporter binding potential (DAT BP) in the striatum of depressed and healthy subjects using [(11)C]RTI-32 PET. The DAT, a predominantly presynaptic receptor, decreases in density after chronic dopamine depletion and the BP is proportional to receptor density. In all striatal regions, subjects with MDE had significantly lower DAT BP. Low striatal DAT BP in MDE is consistent with a downregulation of DAT in response to a dopamine lowering process. There was also a strong, highly significant, inverse correlation between striatal DAT BP and neuropsychological tests of dopamine-implicated symptoms in patients (i.e. patients with lower DAT BP performed better). Lower DAT BP itself reduces extracellular clearance of dopamine. Patients who did not decrease their striatal DAT BP failed to compensate for low dopamine and showed greater impairment on dopamine related tests.
Subject(s)
Cocaine/analogs & derivatives , Corpus Striatum/metabolism , Depressive Disorder, Major/diagnostic imaging , Depressive Disorder, Major/metabolism , Membrane Glycoproteins , Membrane Transport Proteins/metabolism , Nerve Tissue Proteins , Adolescent , Adult , Carbon Radioisotopes , Dopamine Plasma Membrane Transport Proteins , Female , Humans , Male , Middle Aged , Neuropsychological Tests , Tomography, Emission-ComputedABSTRACT
OBJECTIVE: Selective serotonin reuptake inhibitors are commonly used to treat major depression; however, the percentage of serotonin (5-HT) transporter (5-HTT) sites occupied during clinical dosing is unknown. This study measured the proportion of 5-HTT sites blocked during paroxetine and citalopram treatment of depression and assessed the relationship between serum paroxetine levels and the proportion of 5-HTT sites blocked. METHOD: Twelve medication-free depressed patients completed a 6-week trial of either paroxetine (N=8) or citalopram (N=4). Striatal 5-HTT binding potential was measured with [(11)C]DASB and positron emission tomography, before and after 4 weeks of treatment. The binding potential is proportional to receptor density. Striatal 5-HTT binding potential was measured twice in six healthy subjects and once in 11 healthy subjects. RESULTS: A significant decrease in striatal 5-HTT binding potential was found after either treatment, compared to changes found over a 4-week period in healthy subjects. For patients treated with 20 mg/day of paroxetine (N=7), the mean proportion of 5-HTT sites occupied was 83%. For patients treated with 20 mg/day of citalopram (N=4), the mean 5-HTT occupancy was 77%. 5-HTT occupancy increased in a nonlinear relationship with serum levels of paroxetine such that a plateau of occupancy around 85% occurred for serum paroxetine levels greater than 28 microg/liter. CONCLUSIONS: During treatment with clinical doses of paroxetine or citalopram, approximately 80% of 5-HTT receptors are occupied. This change in 5-HTT binding potential is greater than the known physiological range of changes in 5-HTT binding potential but may be necessary for some therapeutic effects.
Subject(s)
Brain/metabolism , Citalopram/pharmacokinetics , Citalopram/therapeutic use , Depressive Disorder, Major/drug therapy , Paroxetine/pharmacokinetics , Paroxetine/therapeutic use , Selective Serotonin Reuptake Inhibitors/pharmacokinetics , Selective Serotonin Reuptake Inhibitors/therapeutic use , Tomography, Emission-Computed , Adult , Binding Sites , Biological Transport/physiology , Caudate Nucleus/metabolism , Chromatography, High Pressure Liquid , Citalopram/blood , Corpus Striatum/metabolism , Female , Gyrus Cinguli/metabolism , Humans , Male , Middle Aged , Paroxetine/blood , Prefrontal Cortex/metabolism , Putamen/metabolism , Regression Analysis , Selective Serotonin Reuptake Inhibitors/blood , Thalamus/metabolismABSTRACT
[(11) C]-DASB, namely [(11) C]-3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)-benzonitrile, is a new highly selective radioligand for the in vivo visualization of the serotonin transporter (SERT) using positron emission tomography (PET). The current study evaluates different kinetic modeling strategies for quantification of [(11)C]-DASB binding in five healthy humans. Kinetic analyses of tissue data were performed with a one-tissue (1CM) and a two-tissue (2CM) compartment model. Time-activity curves were well described by a 1CM for all regions. A 2CM model with four parameters failed to converge reliably. Reliable fits of the data were obtained only if no more than three parameters were allowed to vary. However, even then, the rate constants k(3) and k(4) were estimated with poor precision. Only the ratio k(3)/k(4) was stable. Goodness of fit was not improved by using a 2CM as compared with a 1CM. The minimal study duration required to obtain stable k(3)/k(4) estimates was 80 minutes. For routine use of [(11)C]-DASB, several simplified methods using the cerebellum as a reference region to estimate nonspecific binding were also evaluated. The transient equilibrium, the linear graphical analysis, the ratio of target to reference region, and the simplified reference tissue methods all gave binding potential values consistent with those obtained with the 2CM. The suitability of [(11)C]-DASB for research on the SERT using PET is thus supported by the observations that tissue data can be described using a kinetic analysis and that simplified quantitative methods, using the cerebellum as reference, provide reliable estimates of SERT binding parameters.
Subject(s)
Aniline Compounds , Carrier Proteins/metabolism , Membrane Glycoproteins/metabolism , Membrane Transport Proteins , Models, Biological , Nerve Tissue Proteins , Radiopharmaceuticals , Sulfides , Tomography, Emission-Computed/methods , Adult , Aniline Compounds/blood , Brain Chemistry , Carbon Radioisotopes , Chromatography, High Pressure Liquid , Computer Simulation , Female , Humans , Kinetics , Male , Middle Aged , Radiopharmaceuticals/blood , Serotonin Plasma Membrane Transport Proteins , Sulfides/bloodABSTRACT
BACKGROUND: Patients with gastro-oesophageal reflux disease (GORD) frequently report that meals high in fat worsen heartburn. Nevertheless, studies to determine whether high fat meals promote gastro-oesophageal reflux have produced conflicting and equivocal conclusions. PATIENTS AND METHODS: To determine, alternatively, whether fat in the small intestinal lumen intensifies the perception of heartburn, we studied 11 patients with typical heartburn from GORD. After being placed on omeprazole to suppress endogenous acid, these fasting subjects underwent oesophageal perfusions with graded doses of HCl at pH values of 1.0, 1.5, 2.0, and 2.5. Oesophageal perfusions were conducted while the duodenum was perfused with saline (control) and again with fat at 8 g/h. RESULTS: Time to onset, intensity, and severity of heartburn varied with dose of oesophageal acid (p<0.01). Time to onset was significantly (p<0.01) shorter, and intensity and severity of heartburn significantly (p<0.05) greater, during duodenal perfusion with fat. CONCLUSION: We conclude that duodenal fat intensifies the perception of heartburn.
Subject(s)
Dietary Fats/administration & dosage , Gastroesophageal Reflux/complications , Gastrointestinal Contents/chemistry , Heartburn/etiology , Adult , Aged , Analysis of Variance , Anti-Ulcer Agents/therapeutic use , Dose-Response Relationship, Drug , Duodenum , Female , Gastroesophageal Reflux/drug therapy , Gastroesophageal Reflux/physiopathology , Heartburn/drug therapy , Heartburn/physiopathology , Humans , Hydrochloric Acid/administration & dosage , Hydrogen-Ion Concentration , Male , Middle Aged , Omeprazole/therapeutic use , Perception , Statistics, NonparametricABSTRACT
To treat pancreatic exocrine insufficiency, physicians often prescribe enterically coated pellets of pancreatin to be taken with meals. The pellets are only partially effective in correcting the digestion and absorption of fat. We sought to determine in normal subjects whether emptying of pellets from the postcibal stomach was dose-related and whether the gastric emptying of lipophilic Creon-20 or Pancrease was altered by the presence or the absence of oil in a meal. Gastric emptying of pellets surface-labeled with 113mIn or 99mTc was followed with a gamma camera for 300 min after isocaloric meals. From our observations, we concluded that gastric emptying of 0.28-1.12 g of 1-mm or 2-mm pellets was dose-related (P < 0.01) and emptying of neither Creon-20 nor Pancrease was much affected by oil in the meal.
Subject(s)
Dietary Fats, Unsaturated/pharmacology , Gastric Emptying , Gastrointestinal Agents/metabolism , Pancrelipase/metabolism , Adult , Female , Gastrointestinal Agents/administration & dosage , Humans , Male , Microspheres , Middle Aged , Pancrelipase/administration & dosageABSTRACT
OBJECTIVE: Depression is commonly associated with frontal hypometabolic activity accompanied by hypermetabolism in certain limbic regions. It is unclear whether successful antidepressant treatments reverse these abnormalities or create new resting levels of metabolism. The aim of the present study was to assess the effects of successful paroxetine treatment on regional glucose metabolism in patients with major depression. METHOD: Positron emission tomography with [(18)F]fluorodeoxyglucose was performed on 13 male patients before and after 6 weeks of paroxetine therapy. Resting state scans were also acquired under similar conditions in 24 healthy male subjects for comparison. RESULTS: After successful paroxetine therapy, increased glucose metabolism occurred in dorsolateral, ventrolateral, and medial aspects of the prefrontal cortex (left greater than right), parietal cortex, and dorsal anterior cingulate. Areas of decreased metabolism were noted in both anterior and posterior insular regions (left) as well as right hippocampal and parahippocampal regions. In comparison to metabolism levels in a group of healthy volunteers, the increase in prefrontal metabolic activity represented a normalization of previously reduced metabolic activity, whereas the reduction in pregenual anterior cingulate activity represented a decrease from previously elevated metabolic levels. CONCLUSIONS: These results provide further support for a dysfunction in cortical-limbic circuitry in depression, which is at least partly reversed after successful paroxetine treatment.
Subject(s)
Brain/metabolism , Depressive Disorder/drug therapy , Glucose/metabolism , Paroxetine/therapeutic use , Selective Serotonin Reuptake Inhibitors/therapeutic use , Tomography, Emission-Computed/statistics & numerical data , Adult , Brain/diagnostic imaging , Brain/drug effects , Depressive Disorder/diagnostic imaging , Depressive Disorder/metabolism , Fluorodeoxyglucose F18 , Functional Laterality , Gyrus Cinguli/diagnostic imaging , Gyrus Cinguli/drug effects , Gyrus Cinguli/metabolism , Hippocampus/diagnostic imaging , Hippocampus/drug effects , Hippocampus/metabolism , Humans , Limbic System/diagnostic imaging , Limbic System/drug effects , Limbic System/metabolism , Male , Middle Aged , Parietal Lobe/diagnostic imaging , Parietal Lobe/drug effects , Parietal Lobe/metabolism , Paroxetine/blood , Paroxetine/pharmacokinetics , Prefrontal Cortex/diagnostic imaging , Prefrontal Cortex/drug effects , Prefrontal Cortex/metabolism , Selective Serotonin Reuptake Inhibitors/blood , Selective Serotonin Reuptake Inhibitors/pharmacokinetics , Treatment OutcomeABSTRACT
PET and SPECT using appropriate radioligands allow imaging of certain critical components of neurotransmission such as presynaptic transporters and postsynaptic receptors in living human brains. PET and SPECT data are commonly analyzed by applying tracer kinetic models. These modeling approaches assume a compartmental system and derive the outcome measure called the binding potential, which reflects the densities of transporters or receptors in a brain region of interest. New models are often noninvasive in that they do not require arterial blood sampling. In this review, the concept and principles of tracer kinetic modeling are introduced and commonly used PET and SPECT neuroreceptor quantification models are discussed.
Subject(s)
Brain/metabolism , Models, Biological , Models, Theoretical , Receptors, Neurotransmitter/metabolism , Tomography, Emission-Computed, Single-Photon , Tomography, Emission-Computed , Humans , Radioligand Assay , Radiopharmaceuticals/pharmacokineticsABSTRACT
Positron emission tomography (PET) and [11C]WAY-100635 were used to examine the effect of age on serotonin-1A (5-HT1A) receptor binding potential (BP) in 19 healthy subjects. Regions of interest (ROI) were drawn on the co-registered magnetic resonance imaging (MRI) in orbitofrontal (OFC), dorsolateral prefrontal (DLPFC), anterior cingulate (ACC), lateral (LTC), and mediotemporal (MTC), parietal, occipital and cerebellar cortex, and the raphe nuclei. BP values were calculated using a simplified reference tissue method. In addition, a voxelwise analysis was performed using SPM99. Voxelwise analysis revealed a significant global decrease of 5-HT(1A) BP with age (set level <.001). ROI analysis revealed significant age-related 5-HT(1A) BP decreases in DLPFC (r = -0.56), ACC (r = -0.44), OFC (r = -0.42), LTC (r = -0.40), parietal (r = -0.65), and occipital cortex (r = -0.43), but not in MTC or raphe nuclei. Overall, cortical 5-HT(1A) BP declined by approximately 10% per decade, except for the MTC, where we did not find a significant age effect. Hence, careful age matching may be recommended for future studies using PET and [11C]WAY-100635 to examine 5-HT1A receptors.
Subject(s)
Aging/metabolism , Brain/metabolism , Neurons/metabolism , Receptors, Serotonin/metabolism , Serotonin/metabolism , Adult , Binding Sites/drug effects , Binding Sites/physiology , Brain/drug effects , Brain Mapping , Carbon Radioisotopes/administration & dosage , Carbon Radioisotopes/pharmacokinetics , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Female , Humans , Image Processing, Computer-Assisted , Male , Middle Aged , Neurons/drug effects , Piperazines/administration & dosage , Piperazines/pharmacokinetics , Pyridines/administration & dosage , Pyridines/pharmacokinetics , Raphe Nuclei/drug effects , Raphe Nuclei/metabolism , Receptors, Serotonin/drug effects , Receptors, Serotonin, 5-HT1 , Serotonin Antagonists/administration & dosage , Serotonin Antagonists/pharmacokinetics , Tomography, Emission-ComputedABSTRACT
BACKGROUND: Noradrenergic dysfunction has been consistently implicated in depression. Much of the evidence, though, has been indirect, such as an attenuated growth hormone response to the alpha2-adrenoceptor agonist clonidine. To more directly examine central functioning of the noradrenergic system in depression, we have used [15O] H2O positron emission tomography (PET) to measure cerebral blood flow (rCBF) in combination with clonidine as a neuromodulatory probe. METHODS: Subjects were six depressed and six healthy women, medication free and matched for age and phase of menstrual cycle. Two PET scans were acquired at baseline and two scans at 20 and 35 min following an intravenous clonidine infusion of 1.4 microg/kg while subjects performed a sustained attention task. RESULTS: The growth hormone response did not show a significant difference between groups. However, PET results revealed a difference in the right superior prefrontal cortex that was resolved as an interaction from decreased rCBF in healthy control subjects but increased rCBF in the depressed group, which was not accounted for by differences in task performance. CONCLUSIONS: This differential effect of clonidine in the right prefrontal cortex provides in vivo evidence of noradrenergic dysfunction in depression, which we postulate arises from functionally impaired presynaptic alpha2-adrenoceptors as well as regionally "supersensitive" postsynaptic cortical alpha2-adrenoceptors.
Subject(s)
Adrenergic alpha-Agonists/pharmacology , Attention/drug effects , Clonidine/pharmacology , Prefrontal Cortex , Tomography, Emission-Computed , Adult , Cerebrovascular Circulation/physiology , Female , Human Growth Hormone/pharmacology , Humans , Prefrontal Cortex/blood supply , Prefrontal Cortex/drug effects , Prefrontal Cortex/physiopathology , Receptors, Adrenergic, alpha/drug effectsABSTRACT
Rats adapt to changes in dietary energy to maintain nearly constant energy intakes. This regulation indicates that animals sense and respond to nutrient content. We sought to determine whether this response was affected by the fat content of the diet. Our second goal was to determine how energy dilution affected intragastric volumes. Rats were randomized to high (18% w/w) and low fat (4.5% w/w) as the energy density of the diet was altered from 2.0 to 3.5 kcal/g. Average energy intake during 7-h feeds rose steeply (P<.01) when density was increased from 2.0 to 3.0 kcal/g, but modestly as density increased from 3.0 to 3.5 kcal/g. In other rats on 18% vs. 32% fat diets, energy intakes increased significantly (P<.01) as density of the diet was raised from 3.5 to 4.5 kcal/g. During diets at 2.0 and 2.5 kcal/g, animals on 18% fat ate fewer kilocalories than those on 4.5% fat; but over 3.0-4.5 kcal/g, energy intake was similar regardless of fat concentration (4.5-32%). Gastric contents after 7-h feeds increased with grams of food ingested similarly for high- and low-fat diets. We concluded that in rats: (a) compensation to energy dilution or concentration was inexact but (b) was about equal for high- vs. low-fat diets; thus, high fat was as well sensed as high carbohydrate; (c) compensations for energy densities were made despite varied gastric volumes; thus, rats learned to override the stimulus of gastric stretch and to sense energy via extra gastric mechanisms.